These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 8875929)

  • 21. The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2.
    Uesugi M; Verdine GL
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14801-6. PubMed ID: 10611293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif.
    Xu H; Ye H; Osman NE; Sadler K; Won EY; Chi SW; Yoon HS
    Biochemistry; 2009 Dec; 48(51):12159-68. PubMed ID: 19916559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism of the interaction between MDM2 and p53.
    Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
    J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A genetic approach to mapping the p53 binding site in the MDM2 protein.
    Freedman DA; Epstein CB; Roth JC; Levine AJ
    Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
    Stoll R; Renner C; Hansen S; Palme S; Klein C; Belling A; Zeslawski W; Kamionka M; Rehm T; Mühlhahn P; Schumacher R; Hesse F; Kaluza B; Voelter W; Engh RA; Holak TA
    Biochemistry; 2001 Jan; 40(2):336-44. PubMed ID: 11148027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
    Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
    FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
    Schon O; Friedler A; Freund S; Fersht AR
    J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
    McCoy MA; Gesell JJ; Senior MM; Wyss DF
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Vassilev LT; Vu BT; Graves B; Carvajal D; Podlaski F; Filipovic Z; Kong N; Kammlott U; Lukacs C; Klein C; Fotouhi N; Liu EA
    Science; 2004 Feb; 303(5659):844-8. PubMed ID: 14704432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
    Shin JS; Ha JH; Chi SW
    Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.
    Chen L; Yin H; Farooqi B; Sebti S; Hamilton AD; Chen J
    Mol Cancer Ther; 2005 Jun; 4(6):1019-25. PubMed ID: 15956260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
    Rosal R; Pincus MR; Brandt-Rauf PW; Fine RL; Michl J; Wang H
    Biochemistry; 2004 Feb; 43(7):1854-61. PubMed ID: 14967026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the transactivation domains of p53 family members: a computational study.
    Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
    BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SWIB and the MDM2 domains are homologous and share a common fold.
    Bennett-Lovsey R; Hart SE; Shirai H; Mizuguchi K
    Bioinformatics; 2002 Apr; 18(4):626-30. PubMed ID: 12016060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.